Irvine Lab researchers found that their CAR T vaccine strategy not only supercharges the engineered immune cells to overcome the suppressive environment of solid tumors, but also teaches naturally occurring immune cells to attack cancer cells beyond those the CAR T cells are designed to target. While the Cell study focuses on glioblastoma and melanoma in mice, the vaccine could be effective for other solid tumors. Elicio Therapeutics is developing this strategy for testing in patients.